ProCE Banner Activity

Phase II TACTI-002 Trial: Updated Results With Eftilagimod Alpha Plus Pembrolizumab as First-line Therapy in Advanced NSCLC

Slideset Download
Conference Coverage
Results from the phase II TACTI-002 trial of the LAG-3 fusion protein eftilagimod alpha in combination with pembrolizumab showed promising durable activity in treatment-naïie patients with advanced NSCLC unselected for PD-L1.

Released: June 07, 2022

Expiration: June 06, 2023

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.


Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab